Bone Density Decline: Tenofovir has been associated with a decrease in bone mineral density, escalating the risk of bone difficulties or fractures. HIV-1 infected subjects on dolutegravir monotherapy demonstrated fast and dose-dependent reduction of antiviral action with declines of HIV-1 RNA copies for each ml. The antiviral response was maintained https://tabviropil76102.blogdanica.com/38530007/not-known-details-about-viropil-side-effects